annual CFI:
$260.06M+$270.29M(+2642.62%)Summary
- As of today (June 28, 2025), RXRX annual cash flow from investing activities is $260.06 million, with the most recent change of +$270.29 million (+2642.62%) on December 31, 2024.
- During the last 3 years, RXRX annual CFI has risen by +$531.80 million (+195.70%).
- RXRX annual CFI is now at all-time high.
Performance
RXRX Cash from investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFI:
-$7.27M-$282.73M(-102.64%)Summary
- As of today (June 28, 2025), RXRX quarterly cash flow from investing activities is -$7.27 million, with the most recent change of -$282.73 million (-102.64%) on March 31, 2025.
- Over the past year, RXRX quarterly CFI has dropped by -$617.00 thousand (-9.27%).
- RXRX quarterly CFI is now -102.64% below its all-time high of $275.46 million, reached on December 31, 2024.
Performance
RXRX quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFI:
$259.44M-$617.00K(-0.24%)Summary
- As of today (June 28, 2025), RXRX TTM cash flow from investing activities is $259.44 million, with the most recent change of -$617.00 thousand (-0.24%) on March 31, 2025.
- Over the past year, RXRX TTM CFI has increased by +$270.98 million (+2348.00%).
- RXRX TTM CFI is now -0.24% below its all-time high of $260.06 million, reached on December 31, 2024.
Performance
RXRX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
RXRX Cash from investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2642.6% | -9.3% | +2348.0% |
| 3 y3 years | +195.7% | -105.1% | +338.0% |
| 5 y5 years | +6751.1% | -962.9% | +10000.0% |
RXRX Cash from investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +195.7% | -102.6% | +8.9% | -0.2% | +338.0% |
| 5 y | 5-year | at high | +195.7% | -102.6% | +96.3% | -0.2% | +195.5% |
| alltime | all time | at high | +195.7% | -102.6% | +96.3% | -0.2% | +195.5% |
RXRX Cash from investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$7.27M(-102.6%) | $259.44M(-0.2%) |
| Dec 2024 | $260.06M(-2642.6%) | $275.46M(-6138.1%) | $260.06M(-1554.1%) |
| Sep 2024 | - | -$4.56M(+9.1%) | -$17.89M(+30.8%) |
| Jun 2024 | - | -$4.18M(-37.1%) | -$13.67M(+18.4%) |
| Mar 2024 | - | -$6.65M(+167.4%) | -$11.54M(+12.8%) |
| Dec 2023 | -$10.23M(-105.3%) | -$2.49M(+617.0%) | -$10.23M(-34.9%) |
| Sep 2023 | - | -$347.00K(-83.1%) | -$15.72M(-141.8%) |
| Jun 2023 | - | -$2.05M(-61.6%) | $37.61M(-15.7%) |
| Mar 2023 | - | -$5.34M(-33.1%) | $44.60M(-76.9%) |
| Dec 2022 | $193.25M | -$7.98M(-115.1%) | $193.25M(+29.7%) |
| Sep 2022 | - | $52.98M(+972.6%) | $148.99M(-252.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | $4.94M(-96.6%) | -$97.87M(-10.2%) |
| Mar 2022 | - | $143.30M(-374.3%) | -$109.02M(-59.9%) |
| Dec 2021 | -$271.74M(+3009.2%) | -$52.24M(-73.1%) | -$271.74M(+21.3%) |
| Sep 2021 | - | -$193.87M(+3020.9%) | -$224.09M(+566.0%) |
| Jun 2021 | - | -$6.21M(-68.0%) | -$33.65M(+22.5%) |
| Mar 2021 | - | -$19.42M(+322.9%) | -$27.47M(+214.3%) |
| Dec 2020 | -$8.74M(+123.5%) | - | - |
| Dec 2020 | - | -$4.59M(+34.0%) | -$8.74M(+110.7%) |
| Sep 2020 | - | -$3.43M(+8684.6%) | -$4.15M(+473.9%) |
| Jun 2020 | - | -$39.00K(-94.3%) | -$723.00K(+5.7%) |
| Mar 2020 | - | -$684.00K | -$684.00K |
| Dec 2019 | -$3.91M | - | - |
FAQ
- What is Recursion Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual CFI year-on-year change?
- What is Recursion Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly CFI year-on-year change?
- What is Recursion Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals TTM CFI year-on-year change?
What is Recursion Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of RXRX is $260.06M
What is the all time high annual CFI for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual cash flow from investing activities is $260.06M
What is Recursion Pharmaceuticals annual CFI year-on-year change?
Over the past year, RXRX annual cash flow from investing activities has changed by +$270.29M (+2642.62%)
What is Recursion Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of RXRX is -$7.27M
What is the all time high quarterly CFI for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly cash flow from investing activities is $275.46M
What is Recursion Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, RXRX quarterly cash flow from investing activities has changed by -$617.00K (-9.27%)
What is Recursion Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of RXRX is $259.44M
What is the all time high TTM CFI for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high TTM cash flow from investing activities is $260.06M
What is Recursion Pharmaceuticals TTM CFI year-on-year change?
Over the past year, RXRX TTM cash flow from investing activities has changed by +$270.98M (+2348.00%)